The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Describe randomized trial data from studies evaluating taxanes in anthracycline-naïve or anthracycline-pretreated metastatic breast cancer patients. Discuss recent findings of randomized trials evaluating docetaxel as neoadjuvant therapy. Compare and contrast efficacy end point data from three adjuvant taxane trials with mature results. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com In the 10 years since their initial licensing in Europe, the taxanes, paclitaxel and docetaxel, have emerged as fundamental drugs in the treatment of breast cancer. Clinically meaningful benefits were first shown in the metastatic setting, and large-scale exploration of their roles in the adjuvant therapy of early-stage disease is ongoing. Benefits have been seen in the neoadjuvant setting as well, mainly with docetaxel. This paper reviews the current roles of the taxanes in the treatment of metastatic and early-stage breast cancer. Also addressed are outstanding issues involving optimal dosing and sequencing, as well as a discussion of the relative merits of each agent in this setting. Clinicians should choose a taxane-based regimen for their patients with breast cancer based on consideration of the pharmacokinetics, clinical activity, and dosing schedule that best meets the patients' needs. At the current time, the pharmacokinetic profile, consistent positive clinical results, and convenience of an intermittent, short-infusion schedule have made docetaxel the preferred taxane for many clinicians treating patients with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cited by
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 305
Current Applications of Nanoemulsions in Cancer Therapeutics
Sánchez-López, E., Guerra, M., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Espina, M., Camins, A., Garcia, M. L., & Souto, E. B. (2019) · Nanomaterials · doi:10.3390/nano9060821 · Cited by 276
Predictive factors for response to docetaxel in human breast cancers
Noguchi, S. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00265.x · Cited by 127
Metadata
- Authors
- Crown, J., O'Leary, M., & Ooi, W.-S.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-02
- Volume
- 9
- Issue
- S2
- Pages
- 24-32
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2154966585
- Cited by
- 249
- References
- 1
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience. https://app.cochat.ai/papers/10.1634/theoncologist.9-suppl_2-24
- The paper
- Crown, J., O'Leary, M., & Ooi, W.-S. (2004). Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience. The Oncologist. https://doi.org/10.1634/theoncologist.9-suppl_2-24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.